Showing results (21-30 of 628) with videos related to
Sort By:
Pageof 63
Pharmacogenomics|August 8, 2022
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary interventionMattia Galli, Luis Ortega-Paz, Francesco Franchi, et al.Therapeutic Advances in Hematology|December 6, 2017
The role of oral anticoagulant therapy in patients with acute coronary syndromeJae Youn Moon, Deepa Nagaraju, Francesco Franchi, et al.Current Treatment Options in Cardiovascular Medicine|March 22, 2014
Platelet function testing in contemporary clinical and interventional practiceFrancesco Franchi, Fabiana Rollini, Jung Rae Cho, et al.Interventional Cardiology Clinics|December 14, 2024
Switching Platelet P2Y12 Receptor Inhibiting TherapiesLuis Ortega-Paz, Fabiana Rollini, Francesco Franchi, et al.Journal of Thrombosis and Thrombolysis|February 14, 2021
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelorDominick J Angiolillo, Latonya Been, Marc Rubinstein, et al.European Journal of Pharmacology|September 6, 2015
Drug-drug interactions between clopidogrel and novel cardiovascular drugsFrancesco Pelliccia, Fabiana Rollini, Giuseppe Marazzi, et al.Expert Review of Cardiovascular Therapy|October 22, 2013
Cangrelor: a review on pharmacology and clinical trial developmentFrancesco Franchi, Fabiana Rollini, Ana Muñiz-Lozano, et al.Journal of Thrombosis and Thrombolysis|September 1, 2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery diseaseMattia Galli, Fabiana Rollini, Latonya Been, et al.International Journal of Cardiology|October 11, 2016
New oral anticoagulants and dual antiplatelet therapy: Focus on apixabanFrancesco Pelliccia, Fabiana Rollini, Giuseppe Marazzi, et al.Expert Opinion on Drug Metabolism & Toxicology|October 16, 2024
Switching from cangrelor to oral P2Y12 inhibitors: a focused review on drug-drug interactionsGiovanni Occhipinti, Luis Ortega-Paz, Francesco Franchi, et al.Pageof 63